Healthcare
Sigyn Therapeutics, Inc.(SIGY)
Live Price
Offline$0.035
-10.26% today
1Y Change
-98.58%
Window
Jun 23, 2025 → Jun 17, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- +33.4%
- Dividend Yield
- 0.0%
Coverage: 249 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sigyn Therapeutics, Inc. (SIGY) is a Healthcare stock with listed on OTC. The stock last traded around $0.04 and down 98.6% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +33.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +33.4%, free cash flow +36.9% with operating margin -32561.7% and ROIC 60.6%. Valuation already assumes a fairly strong business story at price/sales 13.6. Stock Foundry combines SIGY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-32561.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +33.4%, while operating margin sits near -32561.7%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SIGY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SIGY Max Drawdown
-99.53%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SIGY and SPY.
Company Overview
Sigyn Therapeutics, Inc.
Other OTC
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.
- Leadership
- James A. Joyce
- IPO Date
- Jan 8, 2021
- Employees
- 4
- Street Address
- 2468 Historic Decatur Road
- Mailing
- San Diego, CA, 92106
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 619-353-0800
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 13.6
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- +33.4%
- Free Cash Flow
- +36.9%
Profitability
- Gross Margin
- 26.4%
- Operating Margin
- -32561.7%
- Net Margin
- -55785.8%
- ROE
- 62.1%
- ROIC
- 60.6%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.